Simpson Thacher represented The Carlyle Group (Carlyle) in connection with the formation and closing of Abingworth’s new Clinical Co-Development Co-Investment Fund (CCD-CIF) at $356 million. Abingworth, a leading international life sciences investment group, is a part of Carlyle. CCD-CIF was significantly oversubscribed, exceeding its target of $300 million.
Alongside the Abingworth Clinical Co-Development Fund 2 (ACCD 2), a fund of $583 million, Abingworth has raised over $930 million in new funds since 2021 to invest in the development of late-stage clinical programs from pharmaceutical and biotechnology companies in the U.S., U.K., Europe and Asia-Pacific, developing innovative therapeutics with potential to significantly improve human health.
The Simpson Thacher team included David Greene, Lina Zhou, Yoonji Woo, Bradley Benson, Jessica Shieh, Joseph Teitelbaum, In Young Kim and Nikaury Payano (Private Funds); and Nancy Mehlman, Jodi Schneider and Lina Pan (Tax).